GB2292143A — Pyrrolo-pyridine derivatives
Assigned to Organon Pharma UK Ltd · Expires 1996-02-14 · 30y expired
What this patent protects
A class of chemical compounds comprising a pyrrolo[2,3-b]-pyridine moiety and a carboxamido-substituted heterocyclic moiety, linked via the 3-position of the pyrrolo[2,3-b]pyridine moiety by a methylene group, are ligands for dopamine receptor subtypes within the body and are the…
USPTO Abstract
A class of chemical compounds comprising a pyrrolo[2,3-b]-pyridine moiety and a carboxamido-substituted heterocyclic moiety, linked via the 3-position of the pyrrolo[2,3-b]pyridine moiety by a methylene group, are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia. The compounds have the formula:- <IMAGE> wherein the broken line represents an optional chemical bond; R<2> is a defined organic radical linked through carbon and A and the remaining R groups are hydrogen atoms or various defined groups.
Drugs covered by this patent
- Zelboraf (vemurafenib) · Hoffmann La Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.